Combat-Ready Brain Health: Mobile AI Diagnostics for TBI

Traumatic Brain Injury (TBI) is the signature injury of modern military service—widespread, underdiagnosed, and operationally debilitating. Since 2000, the DoD has reported over 485,000 diagnosed TBIs, with studies estimating that up to 50% of mild cases (mTBI) go unreported. These injuries degrade cognition, impair decision-making, and elevate the risk of PTSD, depression, suicide, and early separation—without obvious physical signs. Current diagnostics rely on subjective methods, lack scalability, and are unavailable at the point of need.This Direct-to-Phase II proposal adapts Senseye’s clinically validated, AI-powered mental health platform into the first objective, mobile diagnostic for TBI. The technology analyzes involuntary ocular and autonomic biomarkers—gaze stability, saccadic latency, pupil response, heart rate variability—using only a smartphone camera. It delivers sub-10-minute, offline-capable assessments without the need for connectivity or clinical supervision. Senseye’s platform has been used by over 3,000 patients, is advancing toward FDA approval for PTSD and MDD, and is commercially deployed in healthcare and pharma applications.The Phase II effort, backed by AFRL, the 59th Medical Wing, and BAMC, will expand Senseye’s biometric models to identify TBI-specific disruptions. Tasks include AI model training, prototype development, field testing across Air Force units, and iterative refinement based on user feedback. The result will be a deployable, secure, CMMC-compliant diagnostic tool fully aligned with military operational needs and ready for Phase III transition.Senseye’s adaptation addresses a critical readiness gap. Undetected mTBI contributes to degraded performance in high-risk roles such as aviation, cyber, and special operations. The tool empowers commanders and medics with real-time physiological insights for triage, post-blast evaluation, and return-to-duty decisions—enabling earlier intervention and reducing long-term disability costs. Integration with Air Force platforms such as BATDOK and MHS GENESIS will streamline deployment.The commercial potential is equally strong. With over 2.8 million TBIs annually in the U.S., and a $10B+ neurodiagnostics market, Senseye offers a scalable solution for urgent care, sports medicine, telehealth, and behavioral health sectors. The firm has raised $30M, generated $1.8M in 2024 revenue, and is projected to reach $8M in 2025. With robust IP, active commercial pilots, and government validation, Senseye is uniquely positioned to transform brain health diagnostics across defense and civilian markets.